ACTengine® IMA203 Combined With mRNA-4203
Phase 1
15
about 4.1 years
18+
4 sites in CA, MA, NY +1
What this study is about
This trial is testing the safety, tolerability, and anti-tumor activity of IMA203 when combined with different doses of mRNA-4203. It includes adults who have previously been treated for unresectable or metastatic cutaneous melanoma (CM) or synovial sarcoma (SS).
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive IMA203
- 2.Receive mRNA-4203
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Number of participants with dose-limiting toxicities (DLTs), Number of treatment emergent adverse events (AEs), AEs of special interest, serious AEs (SAEs), changes in laboratory parameters and vital signs, and frequency of dose interruptions, reductions and discontinuations
Secondary: Disease control rate (DCR), Duration of response (DOR), Objective response rate (ORR), Progression-free survival (PFS)
Oncology